Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Localized T3 production modifies the transcriptome and promotes the hepatocyte-like lineage in iPSC-derived hepatic organoids
Jorge Hidalgo-Álvarez, Federico Salas-Lucia, Diana Vera Cruz, Tatiana L. Fonseca, Antonio C. Bianco
Jorge Hidalgo-Álvarez, Federico Salas-Lucia, Diana Vera Cruz, Tatiana L. Fonseca, Antonio C. Bianco
View: Text | PDF
Research Article Endocrinology Metabolism

Localized T3 production modifies the transcriptome and promotes the hepatocyte-like lineage in iPSC-derived hepatic organoids

  • Text
  • PDF
Abstract

Thyroid hormone (TH) levels are low during development, and the deiodinases control TH signaling through tissue-specific activation or inactivation of TH. Here, we studied human induced pluripotent stem cell–derived (iPSC-derived) hepatic organoids and identified a robust induction of DIO2 expression (the deiodinase that activates T4 to T3) that occurs in hepatoblasts. The surge in DIO2-T3 (the deiodinase that activates thyroxine [T4] to triiodothyronine [T3]) persists until the hepatoblasts differentiate into hepatocyte- or cholangiocyte-like cells, neither of which expresses DIO2. Preventing the induction of the DIO2-T3 signaling modified the expression of key transcription factors, decreased the number of hepatocyte-like cells by ~60%, and increased the number of cholangiocyte-like cells by ~55% without affecting the growth or the size of the mature liver organoid. Physiological levels of T3 could not fully restore the transition from hepatoblasts to mature cells. This indicates that the timed surge in DIO2-T3 signaling critically determines the fate of developing human hepatoblasts and the transcriptome of the maturing hepatocytes, with physiological and clinical implications for how the liver handles energy substrates.

Authors

Jorge Hidalgo-Álvarez, Federico Salas-Lucia, Diana Vera Cruz, Tatiana L. Fonseca, Antonio C. Bianco

×

Figure 4

Expression of TFs involved in liver development.

Options: View larger image (or click on image) Download as PowerPoint
Expression of TFs involved in liver development.
(A–J) Relative mRNA lev...
(A–J) Relative mRNA levels of TFs (GATA4, FOXA2, FOXA1, PROX1, HHEX, HNF1A, HNF4A, CEBPA, HNF1B, ONECUT1) involved in the network regulation of the hepatic organoids from day 10 to day 46 in V-HOs (black) and T4-HOs (red) (n = 4 except T4-HOs at day 42, n = 2; day 46, n = 3; T4-HOs at day 18 in FOXA2, PROX1, and at day 10 in HHEX n = 3; and V-HOs at D29 in HHEX, n = 3). β-Actin was used as the internal control. The yellow square represents the hepatoblast expansion (HBO), and the purple squares indicate the period of hepatocyte and cholangiocyte maturation (HO1-2). Two-tailed Student’s t test was used to compare groups each day. Data are the mean of duplicates and represented as aligned scatter dot plots. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The days of the differentiation are shown on the x axis (see Figure 1).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts